Furthermore, the synergistic combination of the JAK1/2 kinase inhibitor ruxolitinib with conventional treatment has demonstrated enhanced efficacy in CRLF2-altered B-ALL [47]. This evidence concerns the gene JAK1 and precursor B-cell acute lymphoblastic leukemia.